Farcast has curated a universe of 549 biomarkers including differential gene/protein in the tumor microenvironment, mutations, epigenetic modifications, immune cell sub-populations, signaling pathway signatures and peripheral plasma factors. Of these, 379 are associated with response while 170 are associated with resistance to PD-1/PD-L1 therapy. This curated set of biomarkers is linked with 21 tumor histologies with melanoma being the most studied followed by lung cancer, breast cancer, renal cell carcinoma (RCC) and several others.